pharmaceuticals / healthcare system / individual regulatory systems / pharmaceutical industry / pharmaceutical innovation / retarget existing out-of-patent products / pharmaceutical developers / healthcare / pharmaceutical / regulatory systems / healthcare systems / health-technology-assessment bodies / manufacturing processes / /
MedicalCondition
rare diseases / rare disease / breast cancer / /
Organization
EPC / Food and Drug Administration / European Medicines Agency / European Commission / European Federation of Pharmaceutical Industries and Associations / European Rare Disease Patients Association / European Union / /
Person
Hans Martens / Andrzej Rys / Susan Boynton / Yann Le Cam / Richard Torbett / /
Position
Chief Economist / Director for Health systems and Products / Chief Executive Officer / Head Regulatory Affairs / Adviser / /
Region
Central Europe / Eastern Europe / Western Europe / /
The views and opinions expressed in this summary paper do not necessarily reflect, and should not be attributed to, the official policy or position of the EPC, Shire, or any individual contributor. Fostering pharmaceutic